SCHEMBL19100325

SCHEMBL19100325

N#Cc1cnc(Cl)nc1-n1nc(F)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 2/20 0.41
▸ CSNK1A1 P48729 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ RPS6KA5 O75582 2/20 0.36
▸ IMPDH2 P12268 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ RAB9A P51151 1/20 0.34
▸ ALDH1A1 P00352 5/20 0.33
▸ HPGD P15428 2/20 0.33
▸ BUB1 O43683 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ HTT P42858 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ RPS6KA4 O75676 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19100753 0.85 CSNK1A1 (0.49) PIN1CSNK1A1CLK4IMPDH2MAPT
SCHEMBL22695443 0.85 PIN1 (0.41) PIN1CSNK1A1CLK4RPS6KA5IMPDH2
SCHEMBL19100643 0.84 PIN1 (0.41) PIN1CSNK1A1CLK4IMPDH2MAPT
SCHEMBL19100496 0.83 RPS6KA5 (0.44) RPS6KA5MAPTRPS6KA4SMN1; SMN2MKNK1
SCHEMBL19100505 0.79 RPS6KA5 (0.39) RPS6KA5MAPTALDH1A1HPGDNPSR1
SCHEMBL28612373 0.78 PIN1 (0.41) PIN1CSNK1A1CLK4RPS6KA5IMPDH2
SCHEMBL19100647 0.76 PIN1 (0.45) PIN1CSNK1A1CLK4RPS6KA5RAB9A
SCHEMBL19100394 0.74 PIN1 (0.40) PIN1CSNK1A1CLK4IMPDH2
SCHEMBL28619153 0.73 MAPT (0.42) PIN1CSNK1A1CLK4RPS6KA5IMPDH2
SCHEMBL28612361 0.72 CSNK1A1 (0.46) PIN1CSNK1A1CLK4RPS6KA5IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 — — EP disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed
EP-3399968-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmatech Limited (KY) 2018-11-14 — — EP disclosed
WO-2017120429-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmasciences, Inc. (US) 2017-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 PIN1 768/4885CSNK1A1 24/4885CLK4 1783/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 PIN1 768/4885CSNK1A1 24/4885CLK4 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback